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CORRESPONDENCE
Global warming and performance of antiepileptic
therapeuticsDear Sir,
During early 1990s, there were 30 million patients with
epilepsy in the world1. They require long-term medi-
cation with various antiepiletic formulations. The effi-
cacy of various therapeutic formulations being offered
to those suffering from an epileptic disorder (Table 1)
could be severely lowered in the face of impending
global warming and frequent occurrence of the El nin˜o
effects. Even though the recommended storage tem-
peratures for various antiepileptics (Table 1) range be-
tween 15–25 C or 15–30 C2, and none requires re-
frigeration facilities, an inadvertent exposure to higher
temperatures could vitiate their therapeutic efficacy.
A new record concerning global temperatures was
established during July 1998, when the average global
temperature reached 15.5 C, and July 1998 was
recorded as the hottest month in nearly 120 years3.
Moreover, high ambient temperatures when accompa-
nied by high humidity would involve enormous trans-
mission of heat to antiepileptics. This was evident dur-
ing the 1995 heatwave in Chicago when the maxi-
mum temperature recorded was 40 C, though the heat-
index, the estimate of radiative and evaporative trans-
fer of heat, was 48.3 C4. The high heat-index in de-
veloping countries when accompanied by poor elec-
tricity supplies would upset electrically-operated cool-
ing facilities5. The cumulative effect of high ambient
temperatures, heat-index and poor air-cooling would
be disastrous on potency and bioavailability of various
antiepileptics.
The antiepileptic formulations (Table 1) with de-
sired storage temperature maxima of 25 or 30 C2,
would not be expected to behave differently from ther-
apeutic agents with identical storage requirements dur-
ing field usage. This is vindicated from the field ef-
ficacy of ampicillin, sulfamethoxazole and trimetho-
prim, storage temperature not exceeding 25 C2, and
acetaminophen and vitamin B2 preparations, storage
temperature not exceeding 30 C2, in Bangladesh dur-
ing the early 1990s. An analysis of 137 brands of the
above four therapeutics, being marketed in various re-
gions of Bangladesh, for residual potency, revealed that
there were 37 sub-standard formulations being offered1059–1311/99/030195 + 02 $12.00/0to the public. Of the 16 brands of acetaminophen and 10
brands of ampicillin that were found to be sub-standard
during the analysis, 11 and eight brands, respectively,
had already been assessed as sub-standard by the reg-
ulatory authorities6.
Table 1: Recommended temperatures for storage of
anti-convulsant agents.
15–25 C Controlled temperature of
15 C–30 C (or 30 C)
Benzodiazepines Barbiturates
 diazepam  phenobarbitonea
 clorazepate Benzodiazepines
 nitrazepam  clonazepam
Phenyltriazine Hydantoins
 Lamotrigine  ethylphenylhydantoin
Oxazolidinediones  phenytoin
 Trimethadone GABA analogues
Miscellaneous  gabapentin, vigabatrin
 Sodium valproate Dicarbamate
 primidone  Felbamate
Succinimides
 Ethosaximide
Around 15 C Methsuximide
Sulphamate
 Topiramate
 Paraldehyde Miscellaneous
 Carbamazepine
aAnd others.
The inimical effects of high temperature and heat-
index3, 4 on various antiepileptics (Table 1) should be
tackled by stabilization against adverse environmental
changes. Efforts have been directed to stabilize live vac-
cines by incorporation of trehalose, deuterium oxide,
pirodavir, or compounds based on electrostatic inter-
vention7. Furthermore, it would be desirable to insist on
distinctive marks on antiepileptic formulation tablets,
vials or capsules, to indicate the desired temperature
for storage. Similar symbols have been mandatory for
inflammables, poisons and radioactive substances.
Well stabilized therapeutic agents directed against
different convulsive disorders (Table 1) would ensure
maintenance of potency and bioavailability in the face
of adverse global environmental change. This would
eliminate any failures or sub-optimal response to oth-
erwise efficient antiepileptic agents in clinical practice.c© 1999 BEA Trading Ltd
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